Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable enzyme-based solutions, announced progress on strategic initiatives including a planned 4-for-1 forward stock split and a corporate rebranding to Quantum Genesis AI Corp. The moves are designed to better position the company for its next phase of development, according to a press release.
The company's Board of Directors has authorized a 4-for-1 forward stock split of its issued and outstanding common stock. The forward split is intended to enhance Quantumzyme's public market profile by recalibrating its capital structure to facilitate greater flexibility, support administrative efficiency in trading, and align the company's share profile with its current stage of development. The split will be submitted for processing only after the completion of the pending corporate name and trading symbol change.
Quantumzyme is in the final stages of changing its name to Quantum Genesis AI Corp., a change that reflects a strategic focus on advancing enzyme innovation through artificial intelligence, computational modeling, and data-driven research. The company anticipates the name and corresponding trading symbol change will be completed in the near term. Immediately following the effectiveness of the new name and symbol, the company intends to submit the forward stock split to FINRA for review.
Naveen Kulkarni, President of Quantumzyme, stated, 'Our planned corporate rebranding and capital structure initiatives are intended to better align the Company's public market profile with its long-term strategic direction. Completing the name and symbol change first establishes a clear foundation, and, subject to regulatory review, the proposed forward stock split is designed to support a more efficient and accessible public share structure as we continue executing on our technology and operational roadmap.'
If approved, the forward stock split will increase the number of outstanding shares while proportionally adjusting the per-share trading price. The company believes this action may provide increased flexibility to support future corporate initiatives. The forward split will not change the company's overall market capitalization and will not affect proportional ownership interests of existing shareholders, except for minor adjustments from fractional shares.
Quantumzyme emphasizes that the forward split remains subject to regulatory review and approval, and there can be no assurance regarding timing or completion. The company expects to provide additional updates through subsequent public disclosures. For more information, visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
Quantumzyme Corp. is a biotransformation company focused on advancing sustainable enzyme-based solutions for pharmaceutical manufacturing. Specializing in green chemistry, the company applies quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts designed to enhance efficiency, reduce waste, and support environmentally responsible production.
